key: cord-0916234-att1mkma
authors: Forthal, Donald
title: Adaptive immune responses to SARS-CoV-2
date: 2021-02-18
journal: Adv Drug Deliv Rev
DOI: 10.1016/j.addr.2021.02.009
sha: 25c0f6ba853c42a44628f4404008ef75ee9eff66
doc_id: 916234
cord_uid: att1mkma

This review focuses on adaptive immune responses against SARS-CoV-2, the coronavirus that causes COVID-19. A great deal of work has been accomplished in a very short period of time to describe adaptive immune responses and to ascertain their roles in determining the course of infection. As with other viral infections, SARS-CoV-2 elicits both antibody and T-cell responses. Whereas antibody responses are likely effective in preventing infection and may participate in controlling infection once established, it is less clear whether or not they play a role in pathogenesis. T cells are likely involved in controlling established infection, but a pathogenic role is also possible. Longer term evaluation is necessary to determine the durability of protective immune responses.

This review will primarily focus on adaptive immunity to SARS-CoV-2 and will cover the potential role of T cells and antibody in pathogenesis and in recovery from infection.

ELISA against S1 after a median time of 60 days, 78% had SARS-CoV-2-specific T cell responses [40] . Schulien, et al. demonstrated SARS-CoV-2-specific CD8+ T cells in eight convalescent individuals who were negative for S and N IgG [41] . Similar findings of Tcell responses in the absence of circulating antibodies were reported by Sekine, et al. [12] . SARS-CoV-2-specific peripheral Tfh cells (especially against S) were shown to correlate with antibody neutralization [42] .

Of particular interest to vaccine development and to understanding pathogenesis will be determining if the presence of cross-reacting T cells, presumably generated by other coronaviruses, play a role in the outcome of SARS-CoV-2 infection.

Antibody responses to pathogens can be measured using assays that determine the ability of an antibody to bind to its cognate antigen or by functional assays, such as those that measure neutralizing activity. IgG, IgM and IgA binding assays against S (or various segments of S) or N can be measured using ELISA, chemiluminescence immunoassays, and various other platforms [43] [44] [45] [46] [47] [48] . Neutralizing assays have made use of infectious SARS-CoV-2, which requires biosafety level 3 (BSL3) or of SARS-CoV-2 S protein pseudotyped with either retroviruses or vesicular stomatitis virus (VSV) [49, 50] . Infectious virus neutralizing assays, pseudotyped-virus neutralizing assays and binding assays have generally correlated with each other [51] [52] [53] [54] [55] . Other types of functional assays, such as those that rely on interactions between the Fc segment of antibody and Fc receptors on natural killer cells or macrophages, have also been used to study SARS-CoV-2 antibody responses [56, 57] .

Anti-S and anti-N binding IgM, IgA, and IgG antibodies become detectable between 7 and 12 days after symptom onset in approximately 50% of COVID-19 patients [48, [58] [59] [60] . Whereas most viral infections elicit measurable IgM prior to IgG, in some patients with COVID-19, IgG precedes IgM [48, 59] . Interestingly, this reversal of the usual order of IgM preceding IgG has also been observed with infections caused by SARS-CoV-1 [61, 62] .

IgM and IgA antibody levels peak at about 2-3 weeks after symptom onset, and they are present in most infected individuals by that time [33, 59, 63] . IgM declines to low or undetectable levels by about 4-5 weeks in most patients [64] . IgG antibody is measurable in 50% of patients by about 10 days and peaks at about 21 days after symptom onset [60] . Nearly all infected patients develop an IgG response [33, 59, 63] . After this peak, levels slowly decline, but remain present in most individuals over a period extending to 5-7 months [65] . Interestingly, anti-N IgG titers decline more rapidly than antibodies directed against the receptor-binding domain (RBD) or S2 [65] .

Neutralizing antibodies develop along a similar timeline, peaking at about 14-21 days [60] and are measurable in nearly all infected individuals [66] . Neutralizing antibodies also decline by 8-12 weeks but are still measurable in the majority of patients by 5-7 months (see below for further discussion) [65, 67] . Although the long-lasting neutralizing antibodies are no doubt IgG, plasma or serum IgM and, less potently, IgA1 anti-S antibodies can also neutralize virus [68] . It should be noted that individuals with low titers or even undetectable levels of neutralizing antibody may still be protected from subsequent infection, as memory B cells are present in recovered patients [69, 70] . The memory B cells continue to undergo somatic hypermutation over six months, possibly due to persistence of antigen in the gut [70] .

Notably, several studies have demonstrated that more severely ill patients generate higher levels of antibody, especially IgG, to either S or N then do patients with milder infections [58, [71] [72] [73] [74] . IgG avidity to the RBD, S and N, which increase over time, was also found to be higher in more severely affected individuals [75, 76] . A similar relationship between antibody levels and severity has been noted for infections with other viruses as well, including SARS-CoV-1 and MERS-CoV [77, 78] . The likely explanation for this is that greater antigen exposure, associated with higher or more persistent viral loads, elicits a greater antibody response. However, it is also possible that antibody responses are involved in the pathogenesis of COVID-19 (see below).

Antibody responses in children seem to differ from those in adults. In a study comparing adults with mild infection, adults with severe infection, children hospitalized with multisystem inflammatory syndrome (MIS-C) and children with COVID-19 but not MIS-C (about half of whom were asymptomatic), higher anti-S IgG, IgM and IgA responses were noted in the adults with severe infection than all other groups [79] . Anti-S antibody titers did not differ between the two pediatric cohorts and the adults with mild infection. In contrast, the anti-N IgG responses were significantly lower in both pediatric cohorts compared to the two adult cohorts. These results suggest that the anti-N response is dependent on age but not on disease severity The authors also observed a modest negative correlation between age and anti-S IgG in the non-MISC-C pediatric patients and a positive correlation between age and anti-N IgG titers in the adults with mild infection [79] . Neutralizing antibody responses were lower among both pediatric groups compared to the two adult groups. Whereas there was a significant decline in neutralizing activity with patient age in the pediatric non-MIS-C group, there was no correlation between neutralizing activity and patient age in either adult group [79] . Overall, these results indicate distinct immune responses, as well as infection courses, in children and adults.

It is of interest for vaccine development, as well as for immunoprophylaxis and immunotherapy, to understand both the epitope specificity and the functional activity of protective antibody responses. Based on animal models, particularly mice, hamsters and non-human primates, it is clear that neutralizing monoclonal antibodies (mAbs) directed against S or against the RBD of S can modulate SARS-CoV-2 infection. For example, Hassan et al. demonstrated in mice transduced with adenovirus encoding human ACE2 (hACE2) that the infusion of a chimeric neutralizing mAb one day before intranasal challenge with SARS-CoV-2 could reduce viral burden in lung and lessen inflammation and weight loss [80] . Another study demonstrated similar protective activity of human mAbs in hACE2-transgenic mice challenged with SARS-CoV-2 and in wild-type BALB/C mice challenged with a mouse-adapted strain of SARS-CoV-2 [81] . The same mAbs given three days prior to challenge in rhesus macaques resulted in no detectable virus in nasal swabs or in bronchioalveolar lavage fluid [81] . Prophylactic use of a neutralizing human mAb has also been effective in reducing lung tissue viral load and weight loss in hamsters [82] . Less effect was observed when mAb was given two hours after virus challenge. Another study in hamsters with a different mAb also demonstrated in vivo protection with reduced lung virus load and less weight loss [83] .

Some neutralizing mAbs also have in vitro Fc-receptor mediated activity [57, 84] . However, to our knowledge, there is no direct evidence that non-neutralizing antibodies that might result in antibody-dependent cellular cytotoxicity (ADCC) or other Fc-receptor mediated antibody activities can prevent or modulate infection.

In humans, convalescent plasma obtained from individuals who have recovered from COVID-19 are being evaluated for both prevention and treatment of established infection. With respect to treatment, there are signals from data obtained outside of randomized trials that when given early, convalescent plasma has some effect on the course of infection. Such plasma may work better when given earlier, and there may be a correlation between efficacy and the neutralizing activity of the plasma [85] . However, a large, open-label randomized clinical trial conducted in India did not support the efficacy of convalescent plasma among hospitalized patients with moderate COVID-19 [86] . There are other large ongoing randomized trials evaluating the use of convalescent plasma in prevention and treatment. mAbs with neutralizing activity are also being evaluated for treatment of mild and severe COVID-19 in randomized clinical studies. Results from one of the ongoing trials have been published and showed a decrease in viral load and in hospitalizations in subjects receiving the mAb [87] .

While awaiting more definitive information on the role of neutralizing antibodies in protecting humans from COVID-19, it is reassuring that persons with prior neutralizing antibodies who were exposed on a fishing vessel to SARS-CoV-2 were not re-infected [88] . Moreover, one patient with re-infection was shown not to have a neutralizing response to the primary infection, suggesting the possibility that such nonresponsiveness allowed re-infection to occur [89] . Finally, in a family of two parents with PCR-confirmed symptomatic SARS-CoV-2 infection, all three of their asymptomatic, repeatedly PCR-negative children had salivary anti-CoV-2 antibodies (predominantly IgA) [90] . This suggests that children may mount an immune response that prevents the establishment of SARS-CoV-2 [90] .

In view of the promising animal data, it is likely that vaccines that can elicit sufficient levels of neutralizing antibodies will at least improve outcomes following SARS-CoV-2 infection.

Given the benefit of passive infusion of neutralizing mAbs in preventing infection in animal models, it is important to characterize the epitopes that bind to such mAbs. Several epitopes within S have been documented to bind to neutralizing antibodies. Inhibition of binding by the RBD to hACE2 is the mechanism by which most neutralizing antibodies inhibit SARS-CoV-2 [57, 91] . However, neutralizing epitopes that do not block ACE2 or that bind outside the RBD have been identified [92] [93] [94] [95] [96] . Presumably, some of these antibodies sterically inhibit RBD-hACE2 interactions or mediate conformational changes that limit binding. mAbs could also neutralize virus by inhibiting fusion, a process that is mediated by the S2 region of the spike protein. Although neutralizing activity occurs with antibodies of several germline genes, there is a strong preference for three Ig heavy change variable genes [91] .

. ADE refers to the phenomenon where antibodies increase viral replication, often through Fc or complement receptors, and has been described in vitro for many viruses [97] . In vivo, ADE may be responsible for most cases of severe dengue virus infections [98, 99] . In addition, ADE has been shown to be involved with the pathogenesis of the coronavirus feline infectious peritonitis virus [100, 101] . In vitro and some in vivo data point to a possible role of ADE in MERS and SARS [102] [103] [104] .

With respect to COVID-19, ADE has been brought up as a concern for vaccines and for proposed convalescent plasma or mAb treatment and as a possible contributor to pathogenesis. However, to date, there have been no reports of worse outcomes among vaccine recipients, and neither clinical trials nor the expanded use of convalescent plasma or mAbs have revealed adverse events related to ADE. In fact, apart from one study in hamsters where antibody treatment appears to have resulted in a non-statistically significant greater weight loss than in untreated animals, there is currently no in vivo evidence of ADE occurring in the setting of SARS-CoV-2 infection [83] .

In addition to concerns raised about vaccines or the therapeutic use of antibodies, the de novo antibody response has the potential for mediating ADE or to contribute to pathogenesis in some other manner. This would be consistent with the fact that severe manifestations of COVID-19 often appear after the first week of illness, at a time when antibody becomes discernible and when viral loads are decreasing [4, 105, 106] .

As noted above, the positive correlation between antibody levels and disease severity is also consistent with a role for pathogenesis in the de novo antibody response against SARS-CoV-2. In this regard, one recent paper, not yet peer reviewed, found an association between antibodies to an epitope in N and disease severity [46] . Finally, although data are lacking, pre-existing antibodies to other CoVs could also affect the outcome of COVID-19 in a deleterious (or beneficial) manner.

Over the brief span of less than one year, much has been learned about SARS-CoV-2-specific adaptive immunity. In many ways, immunity appears to be similar to that elicited by other viral infections. In that regard, it is likely that vaccine-mediated protection will rely on neutralizing antibodies and that an adequate and durable response will require T-cell help. In addition, it is likely that T cells will contribute to controlling established infection. However, critical questions remain unanswered. Although, neutralizing antibodies are very likely sufficient for preventing infection or, when given early after infection, able to modify the disease course, their potential role in pathogenesis remains unclear. Similarly, whether or not SARS-CoV-2-specific T cells can prevent infection or play a role in pathogenesis is unknown. Since viruses evolve under immune pressure, it is important to be vigilant for SARS-CoV-2 strains that evade infection-induced or vaccine-induced humoral or cellular immunity. Fascinating uncertainties remain regarding whether immunity to other coronaviruses contribute to COVID-19 outcomes and whether exposure to SARS-CoV-2 can result in an immune response in the absence of demonstrable virus replication. Finally, the durability of both humoral and T-cell immunity acquired after infection is necessarily uncertain, given the short period of experience with the pathogen. 

Clinical and immunological features of severe and moderate coronavirus disease 2019

Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Clinical features of patients infected with 2019 novel coronavirus in

A dynamic COVID-19 immune signature includes associations with poor prognosis

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Comprehensive mapping of immune perturbations associated with severe COVID-19

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19

Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Sex differences in immune responses that underlie COVID-19 disease outcomes

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells

Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression

A dynamic COVID-19 immune signature includes associations with poor prognosis

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition

SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Peripheral CD4 + T cell subsets and antibody response in COVID-19 convalescent individuals

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Early Release -Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG

Characterization of pre-existing and induced SARS-CoV-2-specific CD8 + T cells

SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivity

Antibody Response to a Nucleocapsid Epitope as a Marker for COVID-19 Disease Severity

Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein

A serological assay to detect SARS-CoV-2 seroconversion in humans

Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes, Vaccines (Basel)

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19

SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Antibody responses to SARS-CoV-2 in patients with COVID-19

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARSassociated coronavirus

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2, MedRxiv

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike

Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients

Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors

Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome

MERS-CoV Antibody Responses 1 Year after Symptom Onset

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Potently neutralizing and protective human antibodies against SARS-CoV-2

A Therapeutic Non-selfreactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

BLAZE-1 Investigators, SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Number 12-December 2020 -Emerging Infectious Diseases journal -CDC

Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

Fc receptors in antibody-dependent enhancement of viral infections

Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route

Antibody-Dependent Enhancement Occurs Upon Re-Infection with the Identical Serotype Virus in Feline Infectious Peritonitis Virus Infection

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Nonhuman Primates

Virological assessment of hospitalized patients with COVID-2019

COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia